NCT00454363 - Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2014

Study Completion Date

December 31, 2014

Conditions

Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1Multiple Endocrine Neoplasia Type 1Pancreatic GlucagonomaPancreatic InsulinomaPancreatic Polypeptide TumorRecurrent Digestive System Neuroendocrine Tumor G1Recurrent Pancreatic Neuroendocrine CarcinomaRegional Digestive System Neuroendocrine Tumor G1Somatostatin-Producing Neuroendocrine Tumor

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH